Developments in the field of biotechnology have been categorized into three ‘waves’ or stages. In the first stage or the ‘green wave’, the industry was dominated by the agricultural applications of biotechnology. This was followed by medical applicat ....see more
The sterility testing market was valued at USD 528.0 Million in 2016 and poised to grow at a CAGR of 12.3% between 2016 and 2021, to reach USD 941.0 Million in 2021. Sterility testing is conducted for the presence or absence of viable microorganisms capable of developing and multiplying under favorable conditions. Sterility testing is used by pharmaceutical & biotechnological companies and medical devices companies to ensure the absence of contaminants in biologics and medical devices.
The global top 10 bioprocess technology market is expected to USD 71.03 Billion by 2021 from USD 39.30 Billion in 2016, at a CAGR of 12.4% between 2016 and 2021. Growth in the biopharmaceutical industry, increase in R&D spending, rising demand for vaccine production, and technological advancements form important growth drivers for this market. On the other hand, stringent regulatory policies and high cost of instruments are restraining market growth for bioprocess technologies.
The top 10 cellular analysis market is expected to reach USD 41.34 Billion by 2021 from USD 28.66 Billion in 2016, at a CAGR of 7.6% during the forecast period. Cellular analysis is used for cell identification, cell interaction, cell viability, cell proliferation, cell structure study, cell signaling/cell transduction, target identification & validation, cell counting, and quality control. Currently, cellular analysis technologies are used in various phases of the drug discovery process, cancer diagnosis (oncology), blood cell analysis, toxicity testing, personalized medicine, pathogen testing, and other applications.
The global transfection reagents and equipment market includes forecast from 2016 to 2021. This market is expected to reach USD 1.02 Billion by 2021 from USD 715.4 Million in 2016, at a CAGR of 7.5% during the forecast period. This growth can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer. Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.
The global rat model market is projected to reach USD 588.9 Million by 2021 from 387.7 Million in 2016, growing at a CAGR of 8.7% during the forecast period. Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. In addition to this, increase in R&D activities in pharmaceutical industries is further stimulating the market growth.
The molecular cytogenetics market is projected to reach USD 2.52 Billion by 2021 from USD 1.55 Billion in 2016, at a CAGR of 10.1% from 2016 to 2021. The high incidence and large economic burden of genetic disorders and cancer and rise in healthcare expenditure has resulted in the increasing use of molecular cytogenetic products in clinical and research laboratories, academic research institutes, and pharmaceutical and biotechnology companies.
The global cell sorting market is projected to reach USD 247.4 Million by 2021, at a CAGR of 7.0% in the forecast period (2016–2021). Factors such as technological advancements in cell sorters, rising funding and investments for development of technologically advanced cell sorters, and growing adoption of cell sorting techniques in research activities are driving the growth of this market. The market is further driven by factors such as the growing prevalence of HIV/AIDS and cancer, expanding pharmaceutical and biotechnology industries, and launch of specific reagents for specific applications. However, factors such as the high cost of instruments and lack of awareness & technical knowledge regarding the use of cell sorters are hampering the growth of this market.
The global PEGylated proteins market is expected to USD 1,137.8 Million by 2021 from USD 690.6 Million in 2016, at a CAGR of 10.5% between 2016 and 2021. The major drivers for the market include increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing focus on strategies to improve protein stability and circulating half-life. The rising opportunities in emerging markets and top-selling biologics drugs going off-patent in the near future will provide new growth opportunities for this market.
The global bioreactors market is expected to reach to USD 1,417 Million by 2021 from USD 955 Million in 2015, at a CAGR of 6.8% between 2015 and 2021. The increase in adoption of single-use technologies, use of hybrid technologies: single-use and stainless steel, growing popularity of single-use bioreactor among biopharmaceutical companies, and growing biologics are spurring the growth of the bioreactors market. However, regulatory concerns related to single-use bioreactors, issues regarding leachable and extractable related to single-use bags is hampering the growth of this market.
The global cancer immunotherapy market is expected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion in 2016, at a CAGR of 14.0% during the forecast period. Market growth can be attributed to the increasing incidence of cancer, rising demand for therapies with minimal adverse effects, increase in adoption of immunotherapy over other treatment options, and enhanced drug development process. However, stringent regulatory policies and the highly consolidated market which may create an obstacle for the entry of small players are the major factors restraining the growth of this market.
The antibody production market is projected reach USD 13.28 Billion by 2021 from USD 7.45 Billion in 2016, growing at a CAGR of 12.3% during the forecast period of 2016 to 2021. The antibody production market is segmented on the basis of process and end users. By process, the market is segmented into upstream processing, downstream processing, and filtration.
The global plasma therapy market is expected to grow from USD 135.6 Million in 2016 to USD 297.6 Million by 2021, at a CAGR of 14.0% from 2016 to 2021. Factors driving the growth of the plasma therapy market include rising incidences of trauma and increasing healthcare expenditure worldwide.
The global viral inactivation market is segmented on the basis of method, product, application, end user, and geography. By method, the market is divided into solvent detergent method, pasteurization, and other methods. The global viral inactivation market was valued at USD 320.5 Million in 2016. This market is expected to grow at a CAGR of 12.3% to reach USD 573.0 Million in 2021.
The global virus filtration market is projected to reach USD 3.25 Billion by 2020 from USD 1.82 Billion in 2015, at a CAGR of 12.3% between 2015 and 2020. Virus filtration is an important operation in the pharmaceutical industry, as it not only ensures if the products are adequately purified and fit for consumption, but also helps to optimize process economics and prevent loss of valuable product.
Medical devices are made of metals, such as stainless steel, aluminum, and ceramic. Many of these materials are not compatible with body tissues and fluids and can cause complications such as infections and blood clots. According to the Centers for Disease Control and Prevention (CDC), around 2,000,000 patients contract hospital-acquired infections (HAIs) every year in the U.S., resulting in 100,000 deaths; HAIs cost the U.S. healthcare system an estimated USD 45 billion annually. In addition, according to the European Centre for Disease, around 4,131,000 patients suffer from healthcare-associated infections every year in Europe. Rise in incidence of HAIs is a major challenge for healthcare providers; therefore, antimicrobial coatings have gained importance in recent years.
Mice models are indispensable tools in research activities with their capability to elucidate human disease processes, due to striking similarities between the anatomy, physiology, and genetics of humans and mice. These advantages promote scientific discovery, understanding of the functions of individual genes, mechanisms of different diseases, and the effectiveness and toxicities of various drug molecules. Mice models are the most popularly used animal models due to their small size, short generation time, accelerated lifespan, low cost, and requirement of less space. These factors help in accelerating the research and development of drug therapies.
The global electrophoresis reagents market is projected to reach USD 1.05 Billion by 2020, at a CAGR of 5.4% from 2015 to 2020. The electrophoresis reagents market witnessed substantial growth and rapid technological advancements in the past few years, which had a positive impact on the overall growth of the market. The advancements have allowed the electrophoresis technique to be used in many new applications.
The Global qPCR reagents market is poised to reach ~USD 1,893.9 Million by 2020 From USD 1,307.0 Million in 2015, growing at a CAGR of 7.7%, during 2015 to 2020. Market growth can be attributed to factors such as rising patient population base for infectious diseases & genetic disorders, coupled with growing geriatric population, technological advancements in the life sciences sector, increasing public-private investments, funds, and grants for PCR-based research, and the successful completion of the human genome project. However, technical limitations associated with qPCR are restraining the growth of this market.
The global human insulin market is poised to reach ~USD 39.13 Billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of human insulin market.
The protein labeling market is expected to reach USD 1,894.5 Million by 2020 from USD 1,089.5 Million in 2015, at a CAGR of 11.7%. Protein labeling is carried out using labeling reagents and kits to label an antibody or other protein, to make a fluorescent probe, enzyme conjugate, biotinylated binding reagent, or iodine-labeled tracer for detecting proteins in tissues, cells, and biochemical assays.
The global nucleic acid labeling market is expected to USD 1,925.7 Million by 2020 from USD 1271.8 Million in 2015, at a CAGR of 8.65% between 2015 and 2020. Nucleic acid can be labeled using several different methods including incorporation of fluorescent tags, biotin, and enzymes. The labeled nucleic acid can be used for a variety of applications, including DNA sequencing, PCR, FISH, microarrays, blotting, and in situ hybridization. This market report studies the potential of reagents & kits and services for various applications by using PCR, nick translation, random primer labeling techniques.
The NGS services market in Europe is expected to reach USD 1,152 Million by 2020 from USD 444 Million in 2015, at a CAGR of 21% from 2015 to 2020. Factors such as rising preference of NGS over other platforms; rapid and cost-efficient sequencing; rising prevalence of inherited diseases; application of genomics in drug discovery; growing prevalence of cancer and other malignant diseases; and partnerships among companies, R&D centers, and universities are expected to drive market growth. However, high dependence on grants for R&D, lack of analytics, and stringent reimbursement policies are likely to restrict the growth of this market to a certain extent.
The global EDS, WDS, EBSD, and Micro-XRF instruments market is segmented on the basis of products, applications, and regions. Based on products, the market is categorized into EDS, WDS, EBSD, and Micro-XRF. The EDS segment accounted for a major share of the market, by product, in 2014. The global EDS, WDS, EBSD, and Micro-XRF instruments market is expected to reach USD 1,529.6 Million by 2019 from USD 403.6 Million in 2014, at a CAGR of 5.6% during the forecast period.
The global laser capture microdissection market is expected to reach USD 124.97 Million by 2020 from USD 72.45 Million in 2015, at a CAGR of 11.52% between 2015 and 2020. Laser capture microdissection (LCM) is a contact- and contamination-free method of isolating specific single cells or entire areas of tissues from a wide variety of samples using a focused laser beam. This technique preserves the original morphology of the dissected tissue sample. This market report studies the potential of instruments, consumables, and software for diagnostics and research and development in the molecular analysis of tissue samples.
The global platelet aggregation devices market is poised to reach a value of 342.4 Million by 2020, growing at a CAGR of 21.0% from 2015 to 2020. Factors such as rising incidences of target diseases, rapid growth in the geriatric population across the globe, technological advancements in platelet aggregometers, and increasing number of industry-academia collaborations and clinical studies are fueling the growth of the global platelet aggregation devices market. However, procedural limitations, unfavorable healthcare reforms in the U.S., and dearth of well trained and skilled professionals are some of the key factors restraining the growth of this market.
The expression vectors market is expected to reach $317.1 Million by 2020 from $242.7 Million in 2015, growing at a CAGR of 5.5% from 2015 to 2020. Major factors driving the growth of this market include the increasing demand of protein-based drugs (biologics); high prevalence of lifestyle diseases, infectious diseases, and genetic disorders; and increasing funding for protein research. On the other hand, high market consolidation, which increases entry barriers, and high cost of protein therapy are the major factors restraining the growth of this market.
Protein purification is a process for isolation of one or a more proteins from a complex mixture, usually consisting of cells or tissues. Protein purification is a necessary step in any protein study, and is performed after measuring the enzyme activity of the given sample through assay processes to confirm the presence of a protein or proteins of interest. The Global Protein Purification and Isolation Market Is Expected to Reach $11 Billion to $12 Billion by 2020
The global molecular weight marker market was valued at $265.36 million in 2014 and is poised to grow at a CAGR of 12.23 % between 2014 and 2019, to reach $472.47 million in 2019. Increased research and development spending by biotechnology and pharmaceutical companies, increasing public funding for life science research, and new innovations in genomics and proteomics research will drive the growth of the molecular weight markers market.
The global cell line development market is expected to reach 3.96 billion by 2019 from $2.2 billion in 2014, and is expected to grow at a CAGR of 12.5% from 2014 to 2019. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America is expected to maintain its leadership position in the market in the coming years.
This global whole exome sequencing market was valued at $326.6 million in 2013 and is expected to grow at a CAGR of 22.0% from 2013 to 2018, to reach $884.1 million by 2018. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America is expected to maintain its leadership in the market in the coming years. Growth in the North American market is likely to be driven by factors such as the increasing use of exome sequencing in rare disease research, increased government funding, and large number of sequencing-related conferences and annual meetings hosted by the U.S.
Transfection is an enabler technology used for many cell based research activities with applications spanning production of recombinant proteins and recombinant cell lines, gene therapy, delivery of therapeutics and also drug discovery. This research report provides a brief description on transfection technologies, its evolution, comparative analysis, market landscape analysis, competitive scenario and emerging technology and application trends.
Biotechnology reagents are the substances or compounds used to detect or synthesize another substance in order to provide a test reading. These reagents are used in the field of research, diagnosis, bioscience, and education.
The life sciences and analytical reagents market report studies the life science and analytical reagents market, by technology, end-users, and applications. The life sciences and analytical reagents market, by technology studied in this report are segmented as life science reagents and analytical reagents; of which life science segment accounted for the largest share of 59.37% of the total market in 2011.
The Global DNA & Gene Chip (microarray) market was valued at $760 million in 2010 and is expected to reach $1,425.2 million by 2015 growing at a CAGR of and 13.4%. The oDNA segment accounted for the largest share – 98% – of the global DNA & gene chip market in 2010.
Brazil Biomaterials Market is expected to reach $1.7 billion in 2015 from $550.2 million in 2008 with a CAGR of 19.5% from 2010 to 2015. In 2009, the orthopedic biomaterial market recorded revenues of $236.5 million or 37.5% of the total biomaterial products market. This is mainly because of increasing application areas and introduction of sophisticated technologies in the biomaterials market. However, the orthopedic biomaterial market is estimated to grow at a CAGR of 17.2% from 2010 to 2015. Cardiovascular biomaterial products market is the second-highest market, contributing 36% of the total biomaterial products market.
This report provides industry analysis, competitive landscape and in-depth market segmentation for all the top 10 drug delivery technologies. It provides market data for the oral delivery system, which still dominates the drug delivery market. In addition, the report also analyzes the market data on emerging drug delivery technologies like needleless injectables, PEGylation technologies and microelectromechanical devices.
The U.S. biopharmaceuticals market is expected to increase to $144 billion by 2016. The growth is expected as a result of the launch of new products, approval of new indications for existing therapies and drugs, and increase in population aged 65 years and above. From 2009 to 2016 the U.S. market revenues are forecasted to grow at a compound annual growth rate (CAGR) of 11.2%.
The top 10 drug discovery technologies play a vital role in the growth of the entire pharmaceutical industry as they are the key contributors in the swift introduction of blockbusters and innovative drugs, which is the most important aspect for the pharmaceutical companies.